Alongside with UpHill, Novartis was able to identify the actions with the lowest compliance and the most frequent non-expected actions when managing Heart Failure.
Heart Failure poses an increasing problem for global healthcare systems and brings dramatic changes in people’s lives.
In developed countries, its prevalence is 1-2% of the population, which means that more than 10 million people in the European Union could be affected. Worldwide, this number is estimated to amount to 26 million people.
Additionally, 74% of heart failure patients suffer from at least one comorbidity. In most western economies, this disease is responsible for about 2% of all healthcare expenditure, and in 2014 it cost €29 billion in the EU.
Evaluation on the time prognostic-modifying therapy should be (re)introduce;
Introduction of Sacubitril/Valsartan in hospitalization treatment;
Follow-up scheduling for assessment/titration.
A tailor-made course using UpHill Simulate
to identify the gaps in the diagnostic and therapeutic approach to Heart Failure, tracking the compliance with the European Cardiology guidelines.
Realistic and intuitive interface
Customized feedback supported by evidence
Short length sessions
Real-time overview of performance
Available on demand
“Clinical simulation is becoming increasingly important. Medicine is an art in constant transformation, so tools such as UpHill Simulate bring an enormous added value! It offers
a detailed clinical environment and allows quick and systematic access to clinical guidelines.”
Customer Solutions Manager
Impact and Insights
24% Average compliance with recommended actions;
Actions with the lowest compliance: follow-up scheduling and introduction of Sacubitril in hospitalization treatment;
At least one non-expected action by each participant;
Most frequent non-expected action: hydroxyprogesterone request.